Please provide your email address to receive an email when new articles are posted on . Women with DCIS who did not identify as white had greater reductions in mental health 2 years after treatment ...

The incidence of invasive breast cancer after conservative treatment for ductal carcinoma in situ (DCIS) decreased by more than 50% over the past 30 years, data from a Dutch cancer registry showed.

January 21, 2010 — The term carcinoma in the phrase ductal carcinoma in situ (DCIS) is misleading and troubling and ought to be dropped, or at least its dropping should be considered, suggest some ...

Surgical resection of the primary tumor in patients with distant metastatic breast cancer at diagnosis: Results of a retrospective series. Background: Ductal carcinoma in situ (DCIS) identified by ...

NEW ORLEANS -- A search for biomarkers to predict recurrence of ductal carcinoma in situ (DCIS) instead showed that a substantial fraction of recurrences had genetically distinct features from the ...

A diagnosis of ductal carcinoma in situ (DCIS) might seem reassuring compared to invasive breast cancer, but recent research paints a more nuanced picture about this condition that affects roughly ...

DCIS is a pre-invasive breast cancer condition with uncertain progression, often leading to aggressive treatment despite its "stage 0" classification. The lack of definitive guidance for DCIS ...

A sequential and prospectively maintained database at the Royal Marsden Hospital, London, was retrospectively searched for women who had received neoadjuvant chemotherapy for primary operable breast ...

This new study focused on the patient perspective following a diagnosis of ductal carcinoma in situ (DCIS), a noninvasive type of breast cancer also referred to as stage 0 or pre-cancer, as well as ...

Learn about Ductal Carcinoma in Situ (DCIS), its diagnosis, treatment options and side effects. Empower yourself with information to navigate this journey with confidence. A diagnosis of ductal ...

LAGUNA HILLS, Calif., Jan. 16, 2025 /PRNewswire/ -- Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug ...